OptimizeRx faces one of its sharpest analyst repricing cycles in months, with three separate target cuts landing on May 13 — the same day Q1 results were digested.
The Street moved quickly after the print. Stifel maintained its Buy but pulled its target from $17 to $14. B. Riley Securities also held Buy, trimming from $11 to $10. Stephens & Co. stayed at Equal-Weight and cut from $10 to $7 — now the lowest target in the consensus. The mean target has come down to roughly $12.33 against a stock trading at $6.34, implying analysts still see significant upside from current levels. But the direction of travel matters: this is the second round of mass target cuts since early March, when Roth Capital slashed from $32 to $18 and B. Riley moved from $28 to $11. The company's analyst return potential reading of 133% looks optically large; it partly reflects how far the stock has fallen relative to targets that were set at higher price levels.
Short interest has been building over the past month and now reflects genuine scepticism. SI reached 11.1% of the free float — up around 13% on a 30-day basis — before easing slightly this week, falling 4.3% from its recent peak to roughly 2.07 million shares. That pullback is modest and has not meaningfully changed the overall picture: more than one in nine shares in the float is borrowed short. The ORTEX short score is 60.8, which has drifted lower from 63.2 a week ago — a mild easing but still in elevated territory. Cost to borrow, at just 0.58%, tells a different story: despite the elevated SI, the borrow market remains loose, and availability has plenty of room relative to what is already shorted. That combination — high SI with cheap, accessible borrow — points to structural short positioning rather than any near-term squeeze dynamic.
Options traders show no particular defensiveness. The put/call ratio at 0.26 is nearly flat against its 20-day average of 0.26, with a z-score essentially at zero. The 52-week range on the PCR runs from 0.05 to 1.33, making the current reading unremarkable. Call-side interest dominates the book, though volume in OPRX options is thin enough that individual orders can shift the ratio. RSI-14 is running at 45, suggesting the stock is neither technically stretched nor deeply oversold.
Valuation multiples are low, and the EV/EBIT factor score ranking of 88th percentile suggests the company screens cheaply against peers on an enterprise-value basis. The P/E multiple at 6.4x has expanded modestly over the past month. The EV/EBITDA at 5.1x has edged higher on the week. Bulls point to OPRX's position in digital pharma-to-physician communications and a strong cash balance as a floor. Bears cite concentration risk among a handful of large pharma clients and the challenge of sustaining growth as a sub-$120 million market cap company competing against better-capitalised platforms. The EPS surprise score at the 74th percentile is a genuine positive — the company has a track record of beating estimates — but that history did not prevent the sharp post-print target cuts this week.
Ownership is concentrated and stable. Whetstone Capital holds roughly 8% of shares, and Michael Weintraub, who appears to be a named individual holder, accounts for another 7.4%. Vanguard added about 78,000 shares in the last reported quarter, while Royce & Associates added roughly 125,000. State Street added 85,000 shares through April 30. None of these moves are dramatic, but the pattern of small accumulation from value-oriented managers at a stock now priced below $7 is worth noting. Recent insider activity was limited to small award-related sells in February and December, all at prices well above the current level.
The next event on the calendar is a Q2 earnings report scheduled for June 9. With targets freshly reset and the stock trading at roughly half where most analysts had their models calibrated just two months ago, that print becomes the near-term checkpoint for whether the Street's revised assumptions are conservative enough — or whether the target-cutting cycle has further to run.
See the live data behind this article on ORTEX.
Open OPRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
